Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICOS Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1028)	2/3/2004 5:11:07 PM
From: Icebrg	Read Replies (1) \| Respond to of 1139

Icos "lost" another drug in the pipeline. Now only IC485 remains of the pipeline drugs. They are lucky to have Cialis. Erik By 2003 year-end, we completed patient follow-up in a Phase 2 clinical study evaluating RTX(TM) (resiniferatoxin) for the treatment of interstitial cystitis. In late January 2004, it was determined that RTX was not effective in relieving patients' symptoms. We will not pursue additional studies of interstitial cystitis.